A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
Public ClinicalTrials.gov record NCT03965845. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4/6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT03965845
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Enrollment
- 53 participants
Conditions and interventions
Conditions
Interventions
- Telaglenestat (CB-839) Drug
- Palbociclib Oral Capsule or Tablet [Ibrance] Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 24, 2019
- Primary completion
- Sep 23, 2021
- Completion
- Sep 23, 2021
- Last update posted
- Sep 18, 2022
2019 – 2021
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Hematology/Oncology | Santa Monica | California | 90095 | — |
| Emory, Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Northwestern University Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| Regions Cancer care Center | Saint Paul | Minnesota | 55101 | — |
| Sarah Cannon Research Institute- Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| MD Anderson | Houston | Texas | 77030 | — |
| South Texas Accelerated Research Therapeutic, LLC | San Antonio | Texas | 78229 | — |
| University of Wisconsin Clinical Science Center | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03965845, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 18, 2022 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03965845 live on ClinicalTrials.gov.